Perflow Medical has received CE mark approval for the Cascade Agile non-occlusive remodelling net (Cascade Agile). Expanding the Cascade product family, a press release reports, the Cascade Agile optimises control for distal and tortuous vessel anatomy during coil embolisation of intracranial aneurysms. The Cascade Agile is the latest addition to Perflow’s portfolio of novel neurovascular devices based on a proprietary technology platform, which includes the stream dynamic neuro-thrombectomy net (Stream Net) and Cascade Net.

The Cascade product family is designed to offer procedural efficiency that, the press release states, is not seen in competitive remodelling devices that necessitate total or partial vessel occlusion. Their net design aims to offer continuous blood flow during cerebral aneurysm repair and coiling. For distal aneurysms with tortuous anatomy, the Cascade Agile’s shorter braid length creates an even more responsive device, which gives physicians the confidence and control they need to safely perform coil embolisation.

In addition to the CE mark, an article highlighting clinical experience with the Cascade Net as a novel approach for the treatment of ruptured intercranial aneurysms has been published in the September issue of Journal of NeuroInterventional Surgery (JNIS).

Danny Farin, CEO of Perflow Medical, comments: “Multicentre clinical experience with the Cascade Net has been very positive to date. Our focus on providing physicians with more intraoperative control and better information to improve decision-making during complex neurovascular procedures has been well received by the market. And our nimble team continues to ideate and respond to unmet needs in the market, which led to developing the Cascade Agile. It is an exciting time, soon we will be publishing our clinical experience with the Stream and Cascade Net, which will fuel our future commercial expansion in and outside of Europe.”

The Cascade product family and Stream Net are commercially available across Europe for the treatment of intracranial aneurysms and acute ischemic stroke, respectively. Perflow products are not approved for clinical use within the USA.